You are here: Industry Insights > Alzheimer

News List

Verubecestat, Atabecestat Not Beneficial for Preventing Alzheimer Disease drugs
April 11, 2019
Verubecestat, Atabecestat Not Beneficial for Preventing Alzheimer Disease.
Combating Alzheimer's by restoring the brain's clean-up crew fiercepharma
April 04, 2019
In the central nervous system, microglia are responsible for scouting around for debris such as damaged neurons and protein plaques, and then cleaning it up in a process known as phagocytosis.
Eisai starts Phase III clinical trial for Alzheimer's drug biospectrumasia
March 25, 2019
Clarity AD is a global placebo-controlled, double-blind, parallel-group……
Eisai, Biogen to advance Alzheimer's drug BAN2401 in Phase III testing following failure of aducanumab firstwordpharma
March 23, 2019
Eisai announced Friday that a Phase III trial has been initiated for the anti-amyloid beta protofibril antibody BAN2401……
Eisai to present latest research on Alzheimer's Disease / Dementia Pipeline biospectrumasia
March 23, 2019
Eisai Co., Ltd. announced that a total of seven presentations highlighting the latest data on its Alzheimer's disease/dementia pipeline……
Biogen, Eisai scrap late-stage studies of aducanumab in Alzheimer's disease as deemed unlikely to hit main goals firstwordpharma
March 21, 2019
Biogen and Eisai said Thursday that Phase III studies of the experimental anti-amyloid beta antibody aducanumab ……
IBM Research to use ML for detecting Alzheimer's biospectrumasia
March 15, 2019
The models built could one day help clinicians to predict this risk with an accuracy of up to 77 percent.
Antiepileptics linked to more hospital days in Alzheimer’s patients pharmaceutical-technology
January 23, 2019
A new study by the University of Eastern Finland has found that use of antiepileptic drugs can lead to more hospital days for people living with Alzheimer’s disease....
United Neuroscience inches closer to Alzheimer’s vaccine prize pharmaphorum
January 22, 2019
A vaccine for Alzheimer’s disease developed by United Neuroscience has cleared a phase IIa trial, and seems to be free of the toxicity that has scuppered earlier candidates.
Aquinnah Pharmaceuticals Receives Grant from Alzheimer's Association, Tau Consortium americanpharmaceuticalreview
January 21, 2019
Aquinnah Pharmaceuticals has been awarded $750,000 from the Tau Pipeline Enabling Program (T-PEP) to advance its drug development programs in tauopathy diseases....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page